Stryker Corp. (NYSE:SYK) expanded the number of seats on its board of directors to nine with the addition of the CEO of Belgian biopharm firm Roch Doliveux.
Kalamazoo, Mich.-based Stryker said Doliveux, UCB’s CEO and executive committee chairman since 2005, is the former CEO of Pierre Fabre Pharmaceuticals and former president of Schering-Plough International.
In return for his service on Stryker’s board, Roch will pull down $115,000 a year and an option to purchase 10,228 shares of stock at $51.82 per share, its June 22 closing price, according to a regulatory filing. Stryker shares were trading at $51.08 in late-day activity.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.